HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Leber's hereditary optic neuropathy: clinical and molecular profile of a Brazilian sample.

AbstractPURPOSE:
The aim of this study was to describe clinical features and search for primary mitochondrial DNA (mtDNA) mutations in 13 unrelated Brazilian patients with Leber's hereditary optic neuropathy (LHON).
METHODS:
Analysis of the G11778A, G3460A, and T14484C mutations was done by polymerase chain reaction and restriction fragment length polymorphism, and mutations were confirmed by direct sequencing. Mean age of onset was 24.5 years and all cases were bilateral.
RESULTS:
Sex ratio (12M:1F) and frequency of simultaneous involvement (9/13) were higher than in other studies. In nine cases there was familial recurrence: 24 male and two female relatives. Ten patients had a mutation: G11778A in six, T14484C in three and one G3460A. The frequency of patients bearing a primary mutation was lower than that described in multicentric studies but similar to that observed among Asians. A higher frequency of the T14484C mutation was detected.
CONCLUSIONS:
The contribution of Amerindians and Africans to the Brazilian mtDNA pool may account for differences in the type and frequency of primary LHON mutations.
AuthorsAndréa Trevas Maciel-Guerra, Luciene Maria Zanchetta, Marcela Scabello Amaral Fernandes, Paula Baloni Andrade, Paulo Maurício do Amor Divino Miranda, Edi Lúcia Sartorato
JournalOphthalmic genetics (Ophthalmic Genet) Vol. 31 Issue 3 Pg. 126-8 (Sep 2010) ISSN: 1744-5094 [Electronic] England
PMID20565249 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • DNA, Mitochondrial
Topics
  • Adolescent
  • Adult
  • Age of Onset
  • Brazil (epidemiology)
  • DNA, Mitochondrial (genetics)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Optic Atrophy, Hereditary, Leber (epidemiology, genetics)
  • Polymerase Chain Reaction
  • Polymorphism, Restriction Fragment Length
  • Sex Ratio
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: